Eli Lilly acquired Pasadena-based Protomer Technologies in a deal valued over $1 billion based on future development and commercial milestones. Lilly previously owned 14% of Protomer; the acquisition gives Lilly Protomer's peptide/protein engineering platform and glucose-sensing insulin program.
Key facts
AnnouncedJul 14, 2021
Deal value$1.0B
Deal typeAcquisition/Merger
Therapeutic areaDiabetes
IndicationsDiabetes
Key assetsGlucose-sensing insulin program
MechanismPeptide and protein engineering platform; glucose-responsive insulin